

LEAD ONCOLOGY PROGRAM

OVARIAN CANCER²

- › One of the most common gynaecologic malignancies
- › Fifth most frequent cause of cancer death in women
- › Accounts for 4% of all cancer diagnosis in women and 5% of all cancer deaths
- › Approximately 26,000 new cases and 17,000 deaths annually in Europe

AEZS-108 is a novel hybrid molecule composed of a synthetic peptide that carries a well-known chemotherapeutic agent, doxorubicin, to the core of cancerous cells. This targeted approach could have less side-effects and be more effective in inhibiting tumor growth than some of the current chemotherapeutic compounds.

AEZS-108

A novel targeted approach in a Phase 2 trial for endometrial and ovarian cancer



ENDOMETRIAL CANCER³

- › Most common gynaecologic malignancy
- › Accounts for 6% of all cancers in women
- › Approximately 38,000 new cases and 9,000 deaths annually in Europe

PHASE 2 CLINICAL TRIAL

- › Up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer)
- › Program initiated in December of 2007 with top-line results expected in early 2009

² (Source: *Gynecologic Oncology*, March 2004, Volume 92, Issue 3, Pages 819-826)

³ (Source: *Annals of Oncology*, 2004 15:1149-1150)